143,238 Shares in Kymera Therapeutics, Inc. $KYMR Bought by Nuveen LLC

Key Points

• Nuveen LLC acquired 143,238 shares of Kymera Therapeutics, valued at approximately $3.92 million, representing ownership of about 0.22% of the company.
• Vanguard Group Inc. also increased its stake in Kymera Therapeutics by 7.0%, owning over 5.23 million shares valued at around $143.2 million.
• Kymera Therapeutics stock is currently rated as a "Buy" by several analysts with a consensus price target of $58.76, despite recent earnings missing estimates.

Nuveen LLC bought a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 143,238 shares of the company's stock, valued at approximately $3,920,000. Nuveen LLC owned approximately 0.22% of Kymera Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of KYMR. Deerfield Management Company L.P. Series C purchased a new stake in Kymera Therapeutics during the fourth quarter valued at $23,856,000. Boxer Capital Management LLC bought a new position in shares of Kymera Therapeutics in the fourth quarter worth about $17,098,000. Janus Henderson Group PLC grew its holdings in shares of Kymera Therapeutics by 2,397.9% in the fourth quarter. Janus Henderson Group PLC now owns 377,384 shares of the company's stock worth $15,197,000 after purchasing an additional 362,276 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Kymera Therapeutics by 7.0% in the first quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company's stock worth $143,183,000 after purchasing an additional 344,080 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Kymera Therapeutics in the fourth quarter worth about $4,610,000.

Kymera Therapeutics Price Performance

Shares of NASDAQ:KYMR traded down $0.55 during trading hours on Monday, hitting $41.20. The company's stock had a trading volume of 596,284 shares, compared to its average volume of 652,019. Kymera Therapeutics, Inc. has a 52 week low of $19.44 and a 52 week high of $53.27. The company has a market capitalization of $2.95 billion, a price-to-earnings ratio of -11.87 and a beta of 2.17. The firm's fifty day moving average price is $43.75 and its 200 day moving average price is $36.81.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.95) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 31.60%. The firm had revenue of $11.48 million during the quarter, compared to the consensus estimate of $17.37 million. During the same quarter in the prior year, the business posted ($0.58) earnings per share. The firm's quarterly revenue was down 55.1% on a year-over-year basis. On average, equities research analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

KYMR has been the topic of a number of research analyst reports. UBS Group cut their price target on shares of Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. BTIG Research restated a "buy" rating and issued a $59.00 price target on shares of Kymera Therapeutics in a report on Thursday, June 26th. Oppenheimer restated an "outperform" rating and issued a $53.00 price target (down from $56.00) on shares of Kymera Therapeutics in a report on Friday, June 27th. The Goldman Sachs Group upgraded shares of Kymera Therapeutics to a "strong-buy" rating in a report on Tuesday, July 15th. Finally, JPMorgan Chase & Co. raised their target price on shares of Kymera Therapeutics from $57.00 to $64.00 and gave the company an "overweight" rating in a research report on Tuesday, June 3rd. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $58.76.

Insider Buying and Selling at Kymera Therapeutics

In other news, Director Jeffrey W. Albers sold 6,349 shares of Kymera Therapeutics stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total transaction of $311,101.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bvf Partners L. P/Il bought 317,167 shares of the business's stock in a transaction dated Monday, June 30th. The shares were purchased at an average cost of $44.00 per share, with a total value of $13,955,348.00. Following the completion of the acquisition, the director owned 2,798,795 shares in the company, valued at approximately $123,146,980. This represents a 12.78% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 48,349 shares of company stock worth $2,334,301 in the last three months. 16.01% of the stock is owned by company insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.